The cream of the healthcare start-up crop will be on display next month at the EIT Health Catapult competition.
Down to the semi-finals stage, EIT Health Catapult has whittled down the start-ups from hundreds of applications to 42, spanning the three areas of Biotech, MedTech and Digital Health.
Beginning with Biotech on the 1st of December the semi-final stages will be run over three days giving investors early access, to those seeking Seed and Series A funding, as these innovators battle it out to be in with a chance of winning some of the prize money, and sponsor prizes, with the prize fund adding up to a total value of €1M.
Currently being put through their paces with individual training sessions and access to industry experts, the companies hoping to bring big change the future of the medical sector will be well prepared ahead of the individual pitches they hope will catapult them through to the final stages of the competition.
Sponsors of the competition include AstraZeneca, Amazon Web Services, eg technology, Lusiadas Saude, Merck, McDermott Will & Emery and Nasdaq proving the high calibre expected from this year’s semi-finalists.
The EIT Health Catapult programme has thrown up many solid investment opportunities over the past six years. It has supported over 200 companies with 98% of past participants still in operation. Now if that stat doesn’t make investors dust off their cheque books, we don’t know what will. That’s an extraordinary strike rate in start-up land.
With one of the programme partners being Nasdaq, one lucky winner will have their name where all the brightest of lights shine, Times Square. The winner of the Audience Award will be displayed on the Nasdaq tower in New York City for all to see – the stuff of dreams.
Participants are in good company as they follow in the footsteps of success stories like gene therapy company Sparing Vision who raised €44.5m just nine months after winning the Biotech category in 2019. Another huge success story to come out of the competition is PhagoMed, who develop phage-based drugs to treat persistent bacterial infections, they have been recently acquired by BioNTech, less than a year after they secured the 2nd place in the Biotech category at EIT Health Catapult.
If you’d like to join this community to watch the cream of healthcare start-ups pitching, update yourself about the most recent healthcare innovations, or are on the lookout for interesting investment opportunities, then logging on to the EIT Health Catapult semi-finals from 1st-3rd December is the place to be. You can also catch some of the keynotes and networking opportunities the community has to offer.
You’ll find all the details you need to register and scope out the participants at EIT Health Catapult Semi-Finals 2021 | EIT Health (eventscase.com).